PE20001282A1 - TRATAMIENTO DE BPH CON AGENTES ELEVADORES DEL cGMP - Google Patents
TRATAMIENTO DE BPH CON AGENTES ELEVADORES DEL cGMPInfo
- Publication number
- PE20001282A1 PE20001282A1 PE1999001053A PE00105399A PE20001282A1 PE 20001282 A1 PE20001282 A1 PE 20001282A1 PE 1999001053 A PE1999001053 A PE 1999001053A PE 00105399 A PE00105399 A PE 00105399A PE 20001282 A1 PE20001282 A1 PE 20001282A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- refers
- bph
- treatment
- nr5r6
- Prior art date
Links
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title abstract 2
- 230000003028 elevating effect Effects 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract 2
- -1 PYRROLIDINYL Chemical class 0.000 abstract 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 abstract 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000000674 adrenergic antagonist Substances 0.000 abstract 1
- 229940029575 guanosine Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 150000004712 monophosphates Chemical class 0.000 abstract 1
- 229960002639 sildenafil citrate Drugs 0.000 abstract 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 abstract 1
- 229930192474 thiophene Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE AL USO DE COMPUESTOS i)DE FORMULA I; R1 ES H, ALQUILO C1-C3, PERFLUOROALQUILO C1-C3, CICLOALQUILO C3-C5; R2 ES H, ALQUILO C1-C6 CON CICLOALQUILO C3-C6, ENTRE OTROS; R3 ES ALQUILO C1-C6 CON CICLOALQUILO C3-C6, ENTRE OTROS; R4 ES ALQUILO C1-C4 CON OH, NR5R6, CN, CONR5R6, CO2R7, ENTRE OTROS; R5 Y R6 SON H, ALQUILO C1-C4 O JUNTO A N FORMAN PIRROLIDINILO, 4-N(R11)-PIPERAZINILO, ENTRE OTROS; R7 ES H, ALQUILO C1-C4; R8 ES ALQUILO C1-C3 CON NR5R6; R9 Y R10 JUNTO CON N FORMAN PIRROLIDINILO, 4-N(R12)-PIPERAZINILO CON ALQUILO C1-C4, NR13R14, ENTRE OTROS; R11 ES H, ALQUILO C1-C3 CON FENILO, (HIDROXI)ALQUILO C2-C3, ALCANOILO C1-C4; R12 ES H, ALQUILO C1-C6, ENTRE OTROS; R13 Y R14 SON H, ALQUILO C1-C4, ENTRE OTROS; DE PREFERENCIA SE REFIERE AL USO DE CITRATO DE SILDENAFIL ii)DE FORMULA II; R0 ES H, HALOGENO, ALQUILO C1-C6; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R2 ES BENCENO, TIOFENO, FURANO, GRUPO a, ENTRE OTROS; ANILLO A ES DE 5-6 MIEMBROS; R3 ES H, ALQUILO C1-C3; R1 Y R3 FORMAN ALQUILO O ALQUENILO DE 3-4 MIEMBROS. TAMBIEN SE REFIERE AL USO JUNTO A UN ANTAGONISTA O-ADRENERGICO; LOS COMPUESTOS INHIBEN A LA GUANOSINA 3`,5'-MONOFOSFATO CICLICO FOSFODIESTERASA TIPO V (GMPc PDEV) Y PUEDEN SER UTILES EN EL TRATAMIENTO DE HIPERPLASIA PROSTATICA BENIGNA (BPH), CONTRACCIONES DE VEJIGA INESTABLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10509798P | 1998-10-21 | 1998-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001282A1 true PE20001282A1 (es) | 2000-11-18 |
Family
ID=22304008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001053A PE20001282A1 (es) | 1998-10-21 | 1999-10-19 | TRATAMIENTO DE BPH CON AGENTES ELEVADORES DEL cGMP |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1020190A3 (es) |
| JP (1) | JP2000128804A (es) |
| KR (1) | KR20000029222A (es) |
| AR (1) | AR020850A1 (es) |
| AU (1) | AU5597799A (es) |
| CA (1) | CA2287122A1 (es) |
| CO (1) | CO5150210A1 (es) |
| HU (1) | HUP9903732A3 (es) |
| IL (1) | IL132406A0 (es) |
| PE (1) | PE20001282A1 (es) |
| ZA (1) | ZA996622B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW536402B (en) | 1998-06-26 | 2003-06-11 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition for the therapy of voiding dysfunction |
| HU225917B1 (en) | 1999-09-16 | 2007-12-28 | Tanabe Seiyaku Co | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| US7273868B2 (en) | 2000-04-28 | 2007-09-25 | Tanabe Seiyaku Co., Ltd. | Pyrazine derivatives |
| CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| IT1318674B1 (it) * | 2000-08-08 | 2003-08-27 | Nicox Sa | Faramaci per l'incontinenza. |
| JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
| JP4396808B2 (ja) | 2001-02-08 | 2010-01-13 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤 |
| EP1364950A4 (en) | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | Pyridopyrimidine and naphthyridine derivatives |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| RU2435588C2 (ru) * | 2005-09-29 | 2011-12-10 | Байер Шеринг Фарма Акциенгезельшафт | Ингибиторы фдэ и их комбинации для лечения урологических расстройств |
| US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| RU2008120332A (ru) * | 2005-12-20 | 2010-01-27 | Пфайзер Продактс Инк. (Us) | Фармацевтическая композиция для лечения luts, содержащая ингибитор pde5 и мускариновый антагонист |
| WO2009045019A2 (en) * | 2007-10-02 | 2009-04-09 | Dong-A Pharm.Co., Ltd. | Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms |
| KR20110062943A (ko) * | 2009-12-04 | 2011-06-10 | 주식회사종근당 | 퀴나졸린 유도체를 유효성분으로 하는 전립선 비대증 예방 또는 치료제 |
| JP6262721B2 (ja) | 2012-05-11 | 2018-01-17 | ジェムバックス アンド カエル カンパニー，リミティド | 敗血症の予防用または治療用の組成物 |
| JP6466833B2 (ja) | 2012-05-11 | 2019-02-06 | ジェムバックス アンド カエル カンパニー，リミティド | 抗炎症活性を有するペプチド、及びそれを含む組成物 |
| WO2014010971A1 (ko) | 2012-07-11 | 2014-01-16 | 주식회사 카엘젬백스 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
| JP6474786B2 (ja) | 2013-04-19 | 2019-02-27 | ジェムバックス アンド カエル カンパニー，リミティド | 虚血性損傷の治療及び予防用の組成物 |
| RU2677277C2 (ru) | 2013-06-07 | 2019-01-16 | Джемвакс Энд Каэл Ко., Лтд. | Биологические маркеры, которые могут быть использованы в иммунотерапии рака |
| KR20160039152A (ko) | 2013-06-21 | 2016-04-08 | 주식회사 젬백스앤카엘 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
| KR101691479B1 (ko) | 2013-10-23 | 2017-01-02 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
| ES2818921T3 (es) | 2013-11-22 | 2021-04-14 | Gemvax & Kael Co Ltd | Péptido que tiene actividad inhibidora de la angiogénesis y composición que contiene el mismo |
| KR102314231B1 (ko) | 2013-12-17 | 2021-10-19 | 주식회사 젬백스앤카엘 | 전립선 암 치료용 조성물 |
| EP3130345B9 (en) | 2014-04-11 | 2022-05-04 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
| KR102232320B1 (ko) | 2014-04-30 | 2021-03-26 | 주식회사 젬백스앤카엘 | 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법 |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| KR102636129B1 (ko) | 2015-02-27 | 2024-02-14 | 주식회사 젬백스앤카엘 | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 |
| ES2886946T3 (es) | 2015-07-02 | 2021-12-21 | Gemvax & Kael Co Ltd | Péptido con efecto antiviral y composición que lo contiene |
| CN117018162A (zh) | 2016-04-07 | 2023-11-10 | 珍白斯凯尔有限公司 | 具有增加端粒酶活性和延长端粒的效果的肽以及组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| DE19540642A1 (de) * | 1995-11-01 | 1997-05-07 | Stief Christian Georg Priv Doz | Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen |
| DE19642322A1 (de) * | 1996-10-14 | 1998-04-16 | Bayer Ag | Neue 3-Heterocyclyl-substituierte Pyrazolderivate |
| DE19709126A1 (de) * | 1997-03-06 | 1998-09-10 | Bayer Ag | Arylamin-, -oxy-, -thio-substituierte Dihydropurinone und Pyrazolopyrimidine |
| CA2295616C (en) * | 1997-07-09 | 2009-05-12 | Christian Georg Stief | Use of phosphodiesterase inhibitors in the treatment of prostatic diseases |
-
1999
- 1999-10-14 IL IL13240699A patent/IL132406A0/xx unknown
- 1999-10-15 EP EP99308148A patent/EP1020190A3/en not_active Withdrawn
- 1999-10-19 PE PE1999001053A patent/PE20001282A1/es not_active Application Discontinuation
- 1999-10-19 CA CA002287122A patent/CA2287122A1/en not_active Abandoned
- 1999-10-20 JP JP11297837A patent/JP2000128804A/ja active Pending
- 1999-10-20 HU HU9903732A patent/HUP9903732A3/hu unknown
- 1999-10-20 AU AU55977/99A patent/AU5597799A/en not_active Abandoned
- 1999-10-20 ZA ZA9906622A patent/ZA996622B/xx unknown
- 1999-10-20 AR ARP990105301A patent/AR020850A1/es not_active Application Discontinuation
- 1999-10-21 KR KR1019990045737A patent/KR20000029222A/ko not_active Ceased
- 1999-10-21 CO CO99066723A patent/CO5150210A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA996622B (en) | 2001-04-20 |
| HU9903732D0 (en) | 1999-12-28 |
| IL132406A0 (en) | 2001-03-19 |
| JP2000128804A (ja) | 2000-05-09 |
| EP1020190A2 (en) | 2000-07-19 |
| HUP9903732A2 (hu) | 2000-08-28 |
| CA2287122A1 (en) | 2000-04-21 |
| AU5597799A (en) | 2000-05-04 |
| AR020850A1 (es) | 2002-05-29 |
| EP1020190A3 (en) | 2000-10-25 |
| HUP9903732A3 (en) | 2002-01-28 |
| CO5150210A1 (es) | 2002-04-29 |
| KR20000029222A (ko) | 2000-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001282A1 (es) | TRATAMIENTO DE BPH CON AGENTES ELEVADORES DEL cGMP | |
| EA200000969A1 (ru) | ИНГИБИТОРЫ цГМБ ФДЭ5 НА ОСНОВЕ ПИРАЗОЛПИРИМИДИНОНА ДЛЯ ЛЕЧЕНИЯ ПОЛОВЫХ ДИСФУНКЦИЙ | |
| PE20020228A1 (es) | Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa | |
| YU108791A (sh) | Pirazolopirimidinon antianginalna jedinjenja | |
| PE20010737A1 (es) | PIRAZOLO [4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| PA8569501A1 (es) | Compuestos utiles en terapia | |
| PE20010736A1 (es) | PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA | |
| PE20030129A1 (es) | Imidazotriazinas | |
| PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
| AR005166A1 (es) | Compuestos de quinolina y quinazolina, su uso, un procedimiento para producirlos, formulaciones farmaceuticas que los incluyen y compuesto utilescomo intermedios en dicho procedimiento. | |
| YU55503A (sh) | Derivati triazolo/4,5-d/pirimidina i njihova primena kao antagonista purinergiskog receptora | |
| BG103828A (en) | PYRAZOLOPYRIMIDINONS INHIBITING CYCLIC GUANOSINE 3', 5'-MONOPHOSPHATE PHOSPHODIESTERASE TYPE 5 (cGMP PDE5), FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
| AU6607901A (en) | Azaindole derivatives, process for their preparation, and their use as antitumoragents | |
| DE60228414D1 (de) | Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten | |
| ES2100572T3 (es) | Esteres de carbonato de la rapamicina como agentes inmunosupresores. | |
| PE20020915A1 (es) | Diaminotiazoles como inhibidores de quinasas dependientes de ciclina | |
| NZ336302A (en) | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia | |
| PE20020756A1 (es) | Imidazotriazinonas sustituidas como inhibidores de la fosfodiesterasa pde 2 | |
| PE20010401A1 (es) | DERIVADOS DE 8-FENIL-6,9-DIHIDRO-[1,2,4] TRIAZOL [3,4-i] PURIN-5-ONA COMO INHIBIDORES DE FOSFODIESTERASA ESPECIFICA DE GMP CICLICO | |
| PE20000011A1 (es) | Combinacion eficaz para el tratamiento de la impotencia | |
| YU55603A (sh) | Derivati purina kao antagonisti purinergiskog receptora | |
| AR033753A1 (es) | Derivados de imidazo[1,5-a]pirimido[5,4-d]benzazepina | |
| PE20040953A1 (es) | Heterociclos biciclicos y procedimientos para su preparacion | |
| PE20030664A1 (es) | DERIVADOS DE TRIAZOLO [4,3-a]PIRIDO[2,3-d]PIRIMIDIN-5-ONA, COMPOSICIONES QUE LOS CONTIENEN, METODO DE PREPARACION Y USO | |
| PE20021043A1 (es) | DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |